Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;7(12):e2445488.
doi: 10.1001/jamanetworkopen.2024.45488.

GOLD COPD Exacerbation History Categories and Disease Outcomes

Affiliations

GOLD COPD Exacerbation History Categories and Disease Outcomes

Kiki Waeijen-Smit et al. JAMA Netw Open. .

Abstract

Importance: Previous exacerbations of chronic obstructive pulmonary disease (ECOPD) are associated with future events. For more than a decade, patients at high risk have been defined as individuals with a history of 2 or more moderate ECOPD, 1 or more severe ECOPD, or both within 12 months, and treatments have been allocated accordingly, but these cutoffs lack validation.

Objectives: To validate ECOPD history categories by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and explore alternative cutoffs to estimate moderate and severe ECOPD and all-cause mortality in COPD.

Design, setting, and participants: This cohort study analyzed data from patients with COPD in the German COPD and Systemic Consequences-Comorbidities Network (COSYCONET) study. Patients were recruited from September 2010 to December 2013. Analyses were conducted in September 2023 to August 2024.

Main outcomes and measures: Risk of moderate and severe (ie, with hospitalization) ECOPD and all-cause mortality over a 4.5-year follow-up period were assessed using binomial logistic regressions and area under the receiver operating characteristic curves (AUROCs) with 95% CIs.

Results: Among 2291 patients with COPD GOLD categories 1 to 4 (mean [SD] age, 65 [8] years; 1396 male [60.9%]), the mean (SD) estimated forced expiratory volume in the first second of expiration was 52.5% (18.6%). ECOPD history categories by GOLD had an AUROC of 0.63 (95% CI, 0.60-0.65) and 0.62 (95% CI, 0.58-0.66) to estimate moderate and severe ECOPD, respectively. A single previous moderate ECOPD within 12 months more accurately estimated future moderate and severe ECOPD (AUROC, 0.66; 95% CI, 0.64-0.69), and in line with GOLD, 1 previous severe ECOPD within 12 months estimated moderate and severe ECOPD (AUROC, 0.63; 95% CI, 0.60-0.67). The 4-year mortality rate was 219 patients (9.6%). Patients with 3 or more previous moderate ECOPD (odds ratio, 2.18; 95% CI, 1.27-3.72) or 1 or more previous severe ECOPD (odds ratio, 1.57; 95% CI, 1.29-1.91) within 12 months were more likely to die compared with patients without prior ECOPD.

Conclusions and relevance: This study's findings suggest a limited estimative performance of ECOPD history categories by GOLD. Novel cutoffs were suggested, categorizing patients as without exacerbations or with high-risk exacerbations based on a history of 1 or more moderate ECOPD, 1 or more severe ECOPD, or both within 12 months.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Bals reported receiving grants from the German Federal Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Schwiete Foundation, and CSL Behring and personal fees from CSL Behrung, GSK, Regeneron, and AstraZeneca outside the submitted work. Dr Rabe reported being a cofounder of Rnatics. Dr Vogelmeier reported receiving personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Grifols, Insmed, Menarini, Novartis, Roche, and Sanofi outside the submitted work. Dr Simons reported receiving grants from Roche and personal fees from AstraZeneca, Chiesi, and GSK paid to the Maastricht University Medical Centre+ outside the submitted work. Dr Franssen reported receiving grants from AstraZeneca and personal fees from AstraZeneca, Chiesi, GSK, MSD, and Sanofi outside the submitted work.

Figures

Figure.
Figure.. Exacerbations of Chronic Obstructive Pulmonary Disease (ECOPD) Risk Estimation
The figure shows area under the receiver operating characteristic curves of the proposed ECOPD history categories vs the current criteria by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to estimate 1-year (visit 2 vs visit 3) moderate ECOPD risk among 1687 patients (A), 1-year severe ECOPD risk among 1688 patients (B), 4-year (visit 2 vs visit 5) moderate ECOPD risk among 861 patients (C), and 4-year severe ECOPD risk among 856 patients (D).

Comment in

  • doi: 10.1001/jamanetworkopen.2024.45457

References

    1. Hurst JR, Vestbo J, Anzueto A, et al. ; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138. doi:10.1056/NEJMoa0909883 - DOI - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease . 2024 GOLD report: global strategy for prevention, diagnosis and management of COPD: 2024 report. Accessed October 11, 2024. https://goldcopd.org/2024-gold-report/
    1. Vestbo J, Hurd SS, Agustí AG, et al. . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-365. doi:10.1164/rccm.201204-0596PP - DOI - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease . 2023 GOLD report: global strategy for prevention, diagnosis and management of COPD: 2023 report. Accessed October 11, 2024. https://goldcopd.org/2023-gold-report-2/
    1. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax. 2011;66(7):585-590. doi:10.1136/thx.2010.152876 - DOI - PubMed

Publication types